Literature DB >> 20567559

New Data on the Use of Biologic Agents for Crohn's Disease and Ulcerative Colitis: Highlights from the 2009 CCFA Advances in IBD Meeting.

Edward V Loftus1.   

Abstract

Entities:  

Year:  2010        PMID: 20567559      PMCID: PMC2886462     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN: 1554-7914


× No keyword cloud information.
  21 in total

1.  Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin.

Authors:  Brian G Feagan; Gordon R Greenberg; Gary Wild; Richard N Fedorak; Pierre Paré; John W D McDonald; Rejean Dubé; Albert Cohen; A Hillary Steinhart; Steven Landau; Rasha A Aguzzi; Irving H Fox; Margaret K Vandervoort
Journal:  N Engl J Med       Date:  2005-06-16       Impact factor: 91.245

Review 2.  Clinical perspectives in Crohn's disease. Objective measures of disease activity: alternatives to symptom indices.

Authors:  Edward V Loftus
Journal:  Rev Gastroenterol Disord       Date:  2007

3.  Natalizumab induction and maintenance therapy for Crohn's disease.

Authors:  William J Sandborn; Jean Frédéric Colombel; Roberts Enns; Brian G Feagan; Stephen B Hanauer; Ian C Lawrance; Remo Panaccione; Martin Sanders; Stefan Schreiber; Stephan Targan; Sander van Deventer; Ronald Goldblum; Darrin Despain; Gary S Hogge; Paul Rutgeerts
Journal:  N Engl J Med       Date:  2005-11-03       Impact factor: 91.245

4.  Management of Crohn's disease in adults.

Authors:  Gary R Lichtenstein; Stephen B Hanauer; William J Sandborn
Journal:  Am J Gastroenterol       Date:  2009-01-06       Impact factor: 10.864

5.  Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin.

Authors:  Brian G Feagan; Gordon R Greenberg; Gary Wild; Richard N Fedorak; Pierre Paré; John W D McDonald; Albert Cohen; Alain Bitton; Jeffrey Baker; Réjean Dubé; Steven B Landau; Margaret K Vandervoort; Asit Parikh
Journal:  Clin Gastroenterol Hepatol       Date:  2008-10-01       Impact factor: 11.382

6.  Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial.

Authors:  Stephan R Targan; Brian G Feagan; Richard N Fedorak; Bret A Lashner; Remo Panaccione; Daniel H Present; Martina E Spehlmann; Paul J Rutgeerts; Zsolt Tulassay; Miroslava Volfova; Douglas C Wolf; Chito Hernandez; Jeffrey Bornstein; William J Sandborn
Journal:  Gastroenterology       Date:  2007-03-21       Impact factor: 22.682

7.  Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial.

Authors:  Gert Van Assche; Charlotte Magdelaine-Beuzelin; Geert D'Haens; Filip Baert; Maja Noman; Séverine Vermeire; David Ternant; Hervé Watier; Gilles Paintaud; Paul Rutgeerts
Journal:  Gastroenterology       Date:  2008-03-08       Impact factor: 22.682

8.  Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial.

Authors:  Stephen B Hanauer; William J Sandborn; Paul Rutgeerts; Richard N Fedorak; Milan Lukas; Donald MacIntosh; Remo Panaccione; Douglas Wolf; Paul Pollack
Journal:  Gastroenterology       Date:  2006-02       Impact factor: 22.682

9.  Certolizumab pegol for the treatment of Crohn's disease.

Authors:  William J Sandborn; Brian G Feagan; Simeon Stoinov; Pieter J Honiball; Paul Rutgeerts; David Mason; Ralph Bloomfield; Stefan Schreiber
Journal:  N Engl J Med       Date:  2007-07-19       Impact factor: 91.245

10.  Maintenance therapy with certolizumab pegol for Crohn's disease.

Authors:  Stefan Schreiber; Mani Khaliq-Kareemi; Ian C Lawrance; Ole Østergaard Thomsen; Stephen B Hanauer; Juliet McColm; Ralph Bloomfield; William J Sandborn
Journal:  N Engl J Med       Date:  2007-07-19       Impact factor: 91.245

View more
  1 in total

Review 1.  Accelerated induction regimens of TNF-alpha inhibitors in patients with inflammatory bowel disease: a scoping review protocol.

Authors:  Amy Johnston; Sabrina Natarajan; Meghan Hayes; Erika MacDonald; Risa Shorr
Journal:  BMJ Open       Date:  2018-01-30       Impact factor: 2.692

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.